Predictors of Mortality in Pulmonary Sarcoidosis

dc.contributor.authorKirkil, Gamze
dc.contributor.authorLower, Elyse E.
dc.contributor.authorBaughman, Robert P.
dc.date.accessioned2026-08-12T17:49:22Z
dc.date.issued2018
dc.departmentFırat Üniversitesi
dc.description.abstractOBJECTIVE: The goal of this study was to assess the prognostic strength of factors in predicting respiratory death in a large cohort of patients with sarcoidosis with at least 8 years' follow-up. METHODS: Data were collected on age, sex, self-declared race, time of death, spirometry findings, diffusing capacity for carbon monoxide, chest radiograph stage, extent of fibrosis on high-resolution CT (HRCT) scanning, and presence of precapillary pulmonary hypertension (PH). The Gender-Age-Physiology (GAP) index and Walsh model criteria for high vs low risk were calculated. RESULTS: A total of 452 patients were identified who had complete pulmonary function testing and chest imaging. The median age at time of entry into the study was 50 years (range, 25-78 years). PH was confirmed by right heart catheterization in 29 (6.4%). Of 452 patients, 42 died during the time of the study, including 38 (8.4%) who died of sarcoidosis-associated respiratory failure and 4 who died of non-sarcoidosis causes. The overall mortality from sarcoidosis was 3.9% and 9.0% at 5 and 10 years, respectively. Alive patients were significantly younger than patients who died from sarcoidosis. Increased mortality was seen for black patients, stage 4 chest radiographs, > 20% fibrosis on HRCT scanning, or PH. The two composite scores (GAP and the Walsh model) were predictive of increased mortality according to univariate analysis. Using the Cox proportional hazards regression model, only age, extent of fibrosis on HRCT scanning, and PH were independent predictors of mortality. CONCLUSIONS: Although most patients with sarcoidosis do well, increased mortality was seen in those patients who were older, had extensive fibrosis on HRCT scanning, or who had PH.
dc.description.sponsorshipMallinckrodt; Gilead; Novartis; Celgene; Bayer; Genentech; National Institutes of Health
dc.description.sponsorshipThe authors have reported to CHEST the following: E. E. L. has received grant support for studies in sarcoidosis by Mallinckrodt, Gilead, Novartis, Celgene, Bayer, and Genentech. R. P. B. has received grant support for studies in sarcoidosis by Mallinckrodt, Gilead, Novartis, Celgene, Bayer, Genentech, and the National Institutes of Health; he has also been a consultant for Gilead, Genentech, Novartis, and Mallinckrodt and is on the speaker bureau for Mallinckrodt and Genentech. None declared (G. K.).
dc.identifier.doi10.1016/j.chest.2017.07.008
dc.identifier.endpage113
dc.identifier.issn0012-3692
dc.identifier.issue1
dc.identifier.pmid28728933
dc.identifier.scopus2-s2.0-85040160809
dc.identifier.scopusqualityQ1
dc.identifier.startpage105
dc.identifier.urihttps://doi.org/10.1016/j.chest.2017.07.008
dc.identifier.urihttps://hdl.handle.net/11508/61777
dc.identifier.volume153
dc.identifier.wosWOS:000422771600022
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Bv
dc.relation.ispartofChest
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectage
dc.subjectfibrosis
dc.subjectsarcoidosis-associated pulmonary hypertension
dc.subjectsurvival
dc.titlePredictors of Mortality in Pulmonary Sarcoidosis
dc.typeArticle

Dosyalar